|AstraZeneca Announces FDA Recommendation for Lesinurad|
|By Silvia Fernandez - Pioneer News|
|Sunday, 25 October 2015 17:35|
Today, pharmaceutical giant AstraZeneca announced that the US Food and Drug Administration Arthritis Advisory Committee (FDA AAC) voted 10-4 in favor of recommending approval for lesinurad 200 mg tablets.
This is a new drug designed for the treatment of hyperuricemia in association with gout and to be used in combination with a separate xanthine oxidase inhibitor.
Indeed, the AAC voted in favor of the drug after reviewing safety and efficacy data during the important Phase III combination therapy trials. This represents the largest clinical trial data set for gout patients to be treated with combination urate lowering therapies.